TY - JOUR
T1 - Brodalumab, an anti-IL17RA monoclonal antibody, in psoriatic arthritis
AU - Mease, Philip J.
AU - Genovese, Mark C.
AU - Greenwald, Maria W.
AU - Ritchlin, Christopher T.
AU - Beaulieu, André D.
AU - Deodhar, Atul
AU - Newmark, Richard
AU - Feng, Jing Yuan
AU - Erondu, Ngozi
AU - Nirula, Ajay
PY - 2014
Y1 - 2014
N2 - BACKGROUND: We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis. METHODS: We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12, patients who had not discontinued their participation in the study were offered open-label brodalumab (280 mg) every 2 weeks. The primary end point was 20% improvement in American College of Rheumatology response criteria (ACR 20) at week 12. RESULTS: Of the 168 patients who underwent randomization (57 in the brodalumab 140-mg group, 56 in the brodalumab 280-mg group, and 55 in the placebo group), 159 completed the double-blind phase and 134 completed 40 weeks of the open-label extension. At week 12, the brodalumab 140-mg and 280-mg groups had higher rates of ACR 20 than the placebo group (37% [P = 0.03] and 39% [P = 0.02], respectively, vs. 18%); they also had higher rates of 50% improvement (ACR 50) (14% [P = 0.05] and 14% [P = 0.05] vs. 4%). Rates of 70% improvement were not significantly higher in the brodalumab groups. Similar degrees of improvement were noted among patients who had received previous biologic therapy and those who had not received such therapy. At week 24, ACR 20 response rates in the brodalumab 140-mg and 280-mg groups were 51% and 64%, respectively, as compared with 44% among patients who switched from placebo to open-label brodalumab; responses were sustained through week 52. At week 12, serious adverse events had occurred in 3% of patients in the brodalumab groups and in 2% of those in the placebo group. CONCLUSIONS: Brodalumab significantly improved response rates among patients with psoriatic arthritis. Larger studies of longer duration are necessary to assess adverse events.
AB - BACKGROUND: We assessed the efficacy and safety of brodalumab, a human monoclonal antibody against interleukin-17 receptor A (IL17RA), in a phase 2, randomized, double-blind, placebo-controlled study involving patients with psoriatic arthritis. METHODS: We randomly assigned patients with active psoriatic arthritis to receive brodalumab (140 or 280 mg subcutaneously) or placebo on day 1 and at weeks 1, 2, 4, 6, 8, and 10. At week 12, patients who had not discontinued their participation in the study were offered open-label brodalumab (280 mg) every 2 weeks. The primary end point was 20% improvement in American College of Rheumatology response criteria (ACR 20) at week 12. RESULTS: Of the 168 patients who underwent randomization (57 in the brodalumab 140-mg group, 56 in the brodalumab 280-mg group, and 55 in the placebo group), 159 completed the double-blind phase and 134 completed 40 weeks of the open-label extension. At week 12, the brodalumab 140-mg and 280-mg groups had higher rates of ACR 20 than the placebo group (37% [P = 0.03] and 39% [P = 0.02], respectively, vs. 18%); they also had higher rates of 50% improvement (ACR 50) (14% [P = 0.05] and 14% [P = 0.05] vs. 4%). Rates of 70% improvement were not significantly higher in the brodalumab groups. Similar degrees of improvement were noted among patients who had received previous biologic therapy and those who had not received such therapy. At week 24, ACR 20 response rates in the brodalumab 140-mg and 280-mg groups were 51% and 64%, respectively, as compared with 44% among patients who switched from placebo to open-label brodalumab; responses were sustained through week 52. At week 12, serious adverse events had occurred in 3% of patients in the brodalumab groups and in 2% of those in the placebo group. CONCLUSIONS: Brodalumab significantly improved response rates among patients with psoriatic arthritis. Larger studies of longer duration are necessary to assess adverse events.
UR - http://www.scopus.com/inward/record.url?scp=84902209516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902209516&partnerID=8YFLogxK
U2 - 10.1056/NEJMoa1315231
DO - 10.1056/NEJMoa1315231
M3 - Article
C2 - 24918373
AN - SCOPUS:84902209516
SN - 0028-4793
VL - 370
SP - 2295
EP - 2306
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 24
ER -